Treatment of postprandial hypotension with selective alpha 1 and beta 1 adrenergic agonists

J Auton Nerv Syst. 1993 Nov;45(2):149-54. doi: 10.1016/0165-1838(93)90126-f.

Abstract

In order to treat postprandial hypotension (PPH), we orally administered a combination of denopamine (10 mg, a selective beta 1-adrenergic agonist) and midodrine-HCl (4 mg, a selective alpha 1-adrenergic agonist) to eight patients with autonomic failure (AF) prior to and after eating. When the patients were given 75 g glucose with 225 ml water without drugs, blood pressure fell subsequently, cardiac output (CO) was unchanged, and vascular resistance of the lower legs (LVR) decreased. However, concomitant administration of denopamine and midodrine-HCl prevented PPH and increased CO and LVR. The portal blood flow was not indifferent to the drugs. A marked increase in heart rate after drug administration was seen in some patients with AF, which reflects the supersensitivity to denopamine. Combined oral administration of denopamine and midodrine-HCl is a safe and useful therapy for PPH in patients with AF.

MeSH terms

  • Adrenergic alpha-Agonists / therapeutic use*
  • Adrenergic beta-Agonists / pharmacology
  • Adrenergic beta-Agonists / therapeutic use*
  • Aged
  • Blood Pressure / drug effects
  • Cardiac Output / drug effects
  • Drug Therapy, Combination
  • Eating
  • Ethanolamines / therapeutic use
  • Female
  • Heart Rate / drug effects
  • Humans
  • Hypotension / drug therapy*
  • Male
  • Middle Aged
  • Midodrine / therapeutic use
  • Plethysmography
  • Receptors, Adrenergic, alpha-1 / drug effects*
  • Receptors, Adrenergic, beta-1 / drug effects*
  • Regional Blood Flow / drug effects
  • Vascular Resistance / drug effects

Substances

  • Adrenergic alpha-Agonists
  • Adrenergic beta-Agonists
  • Ethanolamines
  • Receptors, Adrenergic, alpha-1
  • Receptors, Adrenergic, beta-1
  • Midodrine
  • denopamine